<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20260630"
  xmlns:country="http://xbrl.sec.gov/country/2026"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20260630.xsd" xlink:type="simple"/>
    <context id="C_20260101to20260630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:CommercialLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-05</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20180301to20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-30</endDate>
        </period>
    </context>
    <context id="C_20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_20240131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_20251201to20251216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-16</endDate>
        </period>
    </context>
    <context id="C_20251231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20250101to20250630_cgenStatementOfLocationIncomeBalanceAxis_cgenResearchAndDevelopmentExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:StatementOfLocationIncomeBalanceAxis">cgen:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_cgenStatementOfLocationIncomeBalanceAxis_cgenResearchAndDevelopmentExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:StatementOfLocationIncomeBalanceAxis">cgen:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_cgenStatementOfLocationIncomeBalanceAxis_cgenSellingAndMarketingExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:StatementOfLocationIncomeBalanceAxis">cgen:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_cgenStatementOfLocationIncomeBalanceAxis_cgenSellingAndMarketingExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:StatementOfLocationIncomeBalanceAxis">cgen:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_cgenStatementOfLocationIncomeBalanceAxis_cgenGeneralAndAdministrativeExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:StatementOfLocationIncomeBalanceAxis">cgen:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_cgenStatementOfLocationIncomeBalanceAxis_cgenGeneralAndAdministrativeExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:StatementOfLocationIncomeBalanceAxis">cgen:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20251231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgen:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <unit id="NIS_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD_per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20260101to20260630" id="FFact_306">0001119774</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_20260101to20260630" id="FFact_307">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="C_20260101to20260630" id="FFact_309">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20260101to20260630"
      id="Fdei_DocumentFiscalPeriodFocus20220803133013452">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentPeriodEndDate
      contextRef="C_20260101to20260630"
      id="Fdei_DocumentPeriodEndDate20250722164707705">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentType
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803132217335">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803135229207">2026</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803132624667">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803132653437">COMPUGEN LTD.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803132710165">26 Harokmim Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803132729395">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803132743972">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220803132757086">IL</dei:EntityAddressCountry>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727223630806"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20250731221914224_xbrl_20220727223630806"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20260729145918756_xbrl_20220727223630806"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      id="Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_1"
      unitRef="usd">10280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_2"
      unitRef="usd">90597000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_5"
      unitRef="usd">75338000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_6"
      unitRef="usd">45759000</us-gaap:OtherShortTermInvestments>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20230728025352671_Fact_5"
      unitRef="usd">39682000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20230728025352671_Fact_6"
      unitRef="usd">9284000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20260729133613435_xbrl_20230728025352671_Fact_5"
      unitRef="usd">680000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260729133613435_xbrl_20230728025352671_Fact_6"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_9"
      unitRef="usd">3429000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_10"
      unitRef="usd">2382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_11"
      unitRef="usd">129409000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_12"
      unitRef="usd">148022000</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20250731215727165"
      unitRef="usd">448000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20250731215731431"
      unitRef="usd">410000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_13"
      unitRef="usd">1314000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_14"
      unitRef="usd">1293000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_15"
      unitRef="usd">4082000</cgen:SeverancePayFundNonCurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_16"
      unitRef="usd">3643000</cgen:SeverancePayFundNonCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_17"
      unitRef="usd">2422000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_18"
      unitRef="usd">2521000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_19"
      unitRef="usd">690000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_20"
      unitRef="usd">681000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_21"
      unitRef="usd">8956000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_22"
      unitRef="usd">8548000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_23"
      unitRef="usd">138365000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_24"
      unitRef="usd">156570000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713620_0"
      unitRef="usd">2155000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713621_1"
      unitRef="usd">2353000</us-gaap:AccountsPayableCurrent>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713621_2"
      unitRef="usd">11456000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713622_3"
      unitRef="usd">10970000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713622_4"
      unitRef="usd">623000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713622_5"
      unitRef="usd">521000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20240730191521156_20220719213713622_4"
      unitRef="usd">5255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20240730191521156_20220719213713622_5"
      unitRef="usd">5676000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713623_6"
      unitRef="usd">3144000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713623_7"
      unitRef="usd">3050000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713623_8"
      unitRef="usd">22633000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713623_9"
      unitRef="usd">22570000</us-gaap:LiabilitiesCurrent>
    <cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20240730191548740_20220719213713624_12"
      unitRef="usd">20360000</cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses>
    <cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20240730191548740_20220719213713625_13"
      unitRef="usd">24943000</cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713624_12"
      unitRef="usd">2400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713625_13"
      unitRef="usd">2439000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713625_14"
      unitRef="usd">4238000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713625_15"
      unitRef="usd">3887000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713627_16"
      unitRef="usd">26998000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713627_17"
      unitRef="usd">31269000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20260630"
      id="Fxbrl_20260729132913295"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20251231"
      id="Fxbrl_20260729132928781"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20251231"
      decimals="INF"
      id="Fxbrl_20220719214834949"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20260630"
      decimals="INF"
      id="F20220719213713628_18"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20251231"
      decimals="INF"
      id="Fxbrl_20220719214917721"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20260630"
      decimals="INF"
      id="F20220719213713628_20"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20260630"
      decimals="INF"
      id="Fxbrl_20220719215055193"
      unitRef="Shares">94724146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20260630"
      decimals="INF"
      id="F20220719213713629_22"
      unitRef="Shares">94724146</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20251231"
      decimals="INF"
      id="Fxbrl_20220719215111705"
      unitRef="Shares">94553191</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20251231"
      decimals="INF"
      id="F20220719213713629_24"
      unitRef="Shares">94553191</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713630_26"
      unitRef="usd">262000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713630_27"
      unitRef="usd">262000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713630_28"
      unitRef="usd">556593000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713631_29"
      unitRef="usd">555876000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20240730190751125_20220719213713630_28"
      unitRef="usd">-31000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20240730190751125_20220719213713631_29"
      unitRef="usd">8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713631_30"
      unitRef="usd">-468090000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713632_31"
      unitRef="usd">-453415000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713632_32"
      unitRef="usd">88734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713632_33"
      unitRef="usd">102731000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20260630"
      decimals="-3"
      id="F20220719213713633_34"
      unitRef="usd">138365000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20251231"
      decimals="-3"
      id="F20220719213713633_35"
      unitRef="usd">156570000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240730192631151_Fact_61"
      unitRef="usd">4778000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240730192631151_Fact_62"
      unitRef="usd">3541000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240730192632885_Fact_61"
      unitRef="usd">4518000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240730192632885_Fact_62"
      unitRef="usd">4065000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240730192634852_Fact_61"
      unitRef="usd">260000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240730192634852_Fact_62"
      unitRef="usd">-524000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_61"
      unitRef="usd">13245000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_62"
      unitRef="usd">11414000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_63"
      unitRef="usd">313000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_64"
      unitRef="usd">280000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_65"
      unitRef="usd">4556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_66"
      unitRef="usd">4606000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_67"
      unitRef="usd">18114000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_68"
      unitRef="usd">16300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240730192637254_Fact_61"
      unitRef="usd">-17854000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240730192637254_Fact_62"
      unitRef="usd">-16824000</us-gaap:OperatingIncomeLoss>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_69"
      unitRef="usd">3191000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_70"
      unitRef="usd">2315000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240730192002297"
      unitRef="usd">-14663000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_72"
      unitRef="usd">-14509000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_71"
      unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_72"
      unitRef="usd">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_75"
      unitRef="usd">-14675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_76"
      unitRef="usd">-14523000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728034213148"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728033938209_xbrl_20220719215810562_Fact_72"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728030537018_Fact_75"
      unitRef="usd">-14714000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728030537018_Fact_76"
      unitRef="usd">-14550000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="Fxbrl_20220719220126329"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="FFact_77"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="Fxbrl_20220719220147427"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="FFact_78"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="Fxbrl_20220720012025614"
      unitRef="Shares">94598696</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="FFact_81"
      unitRef="Shares">94598696</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="Fxbrl_20220720012118943"
      unitRef="Shares">92917554</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="FFact_82"
      unitRef="Shares">92917554</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727223132738_Fact_109"
      unitRef="Shares">89541246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_110"
      unitRef="usd">248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_111"
      unitRef="usd">543413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203355538"
      unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_112"
      unitRef="usd">-488758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_113"
      unitRef="usd">54914000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20250731221914224_xbrl_20220727222823749_Fact_114"
      unitRef="Shares">32470</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20250731221914224_xbrl_20220727222823749_Fact_116"
      unitRef="usd">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250731221914224_xbrl_20240730203617529"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250731221914224_xbrl_20220727222823749_xbrl_20220720104943489"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20250731221914224_xbrl_20220727222823749_Fact_117"
      unitRef="usd">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_96"
      unitRef="Shares">3961641</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223710614"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_98"
      unitRef="usd">8859000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20250731222229784"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_xbrl_20220720104851290"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_99"
      unitRef="usd">8870000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">987000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">987000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105044504"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105025339"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730204146662"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_128"
      unitRef="usd">-14523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_129"
      unitRef="usd">-14523000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260729143204018_xbrl_20220727223132738_Fact_109"
      unitRef="Shares">93535357</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20260729143204018_xbrl_20220727223132738_Fact_110"
      unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20260729143204018_xbrl_20220727223132738_Fact_111"
      unitRef="usd">553294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20260729143204018_xbrl_20240730203355538"
      unitRef="usd">-16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260729143204018_xbrl_20220727223132738_Fact_112"
      unitRef="usd">-503281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20250630"
      decimals="-3"
      id="Fxbrl_20260729143204018_xbrl_20220727223132738_Fact_113"
      unitRef="usd">50256000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_109"
      unitRef="Shares">94553191</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_110"
      unitRef="usd">262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_111"
      unitRef="usd">555876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203526337"
      unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_112"
      unitRef="usd">-453415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_113"
      unitRef="usd">102731000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823749_Fact_114"
      unitRef="Shares">141310</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_116"
      unitRef="usd">147000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203617529"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_xbrl_20220720104943489"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_117"
      unitRef="usd">147000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cgen:StockIssuedDuringPeriodSharesCommonStockIssuedForRsusVesting
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260729145918756_xbrl_20220727222823749_Fact_114"
      unitRef="Shares">29645</cgen:StockIssuedDuringPeriodSharesCommonStockIssuedForRsusVesting>
    <cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20260729145918756_xbrl_20220727222823749_Fact_116"
      unitRef="usd">0</cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting>
    <cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20260729145918756_xbrl_20240730203617529"
      unitRef="usd">0</cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting>
    <cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260729145918756_xbrl_20220727222823749_xbrl_20220720104943489"
      unitRef="usd">0</cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting>
    <cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20260729145918756_xbrl_20220727222823749_Fact_117"
      unitRef="usd">0</cgen:StockIssuedDuringPeriodValueCommonStockIssuedForRsuVesting>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20260729224935675_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20260729224935675_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">570000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20260729224935675_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260729224935675_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20260729224935675_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">570000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20240730203654521"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105044504"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105025339"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203708038"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_128"
      unitRef="usd">-14675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_129"
      unitRef="usd">-14675000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_130"
      unitRef="Shares">94724146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_131"
      unitRef="usd">262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_132"
      unitRef="usd">556593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730204035595"
      unitRef="usd">-31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_133"
      unitRef="usd">-468090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_134"
      unitRef="usd">88734000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728044607285"
      unitRef="usd">-14675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728044615653"
      unitRef="usd">-14523000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_137"
      unitRef="usd">570000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_138"
      unitRef="usd">987000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_139"
      unitRef="usd">140000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_140"
      unitRef="usd">235000</us-gaap:Depreciation>
    <cgen:AmortizationOfDiscountOnMarketableSecurities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728052415879_Fact_139"
      unitRef="usd">127000</cgen:AmortizationOfDiscountOnMarketableSecurities>
    <cgen:AmortizationOfDiscountOnMarketableSecurities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728052415879_Fact_140"
      unitRef="usd">310000</cgen:AmortizationOfDiscountOnMarketableSecurities>
    <cgen:SeverancePayNet
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010915535_xbrl_20240731010405127_xbrl_20240301111210380"
      unitRef="usd">-88000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010915535_xbrl_20240731010405127_xbrl_20240301111218731"
      unitRef="usd">-2000</cgen:SeverancePayNet>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010405127_xbrl_20240301111210380"
      unitRef="usd">749000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010405127_xbrl_20240301111218731"
      unitRef="usd">166000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20260729153043600"
      unitRef="usd">2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20260729153100659"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_145"
      unitRef="usd">-214000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_146"
      unitRef="usd">-229000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnShortTermBankDeposits
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010448920_xbrl_20230214015508662"
      unitRef="usd">660000</cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnShortTermBankDeposits>
    <cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnShortTermBankDeposits
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010448920_Fact_0000000000236"
      unitRef="usd">62000</cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnShortTermBankDeposits>
    <cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnLongTermBankDeposits
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20250801025659983"
      unitRef="usd">38000</cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnLongTermBankDeposits>
    <cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnLongTermBankDeposits
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20250801025719594"
      unitRef="usd">28000</cgen:IncreaseDecreaseInInterestReceivablesAndExchangeDifferencesOnLongTermBankDeposits>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010456201_Fact_0000000000238"
      unitRef="usd">680000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010456201_Fact_0000000000239"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010511242_Fact_0000000000241"
      unitRef="usd">1047000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010511242_Fact_0000000000242"
      unitRef="usd">1023000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728053037345"
      unitRef="usd">21000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_154"
      unitRef="usd">-150000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20220719232044563"
      unitRef="usd">-308000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728053025234"
      unitRef="usd">-39000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010554260_xbrl_20230214015610319"
      unitRef="usd">-327000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010554260_Fact_0000000000251"
      unitRef="usd">-466000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_159"
      unitRef="usd">-52000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_160"
      unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010540990_xbrl_20240228013913681_xbrl_20230214015610319"
      unitRef="usd">4097000</cgen:IncreaseDecreaseInDeferredRevenues>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010540990_xbrl_20240228013913681_Fact_0000000000251"
      unitRef="usd">3540000</cgen:IncreaseDecreaseInDeferredRevenues>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_163"
      unitRef="usd">-21947000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_164"
      unitRef="usd">-18564000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_165"
      unitRef="usd">37744000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_166"
      unitRef="usd">40896000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_167"
      unitRef="usd">66663000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_168"
      unitRef="usd">37972000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728052423298_Fact_139"
      unitRef="usd">8970000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728052423298_Fact_140"
      unitRef="usd">21643000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728052426602_Fact_139"
      unitRef="usd">39280000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728052426602_Fact_140"
      unitRef="usd">26606000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20260729153134926_xbrl_20230728052426602_Fact_139"
      unitRef="usd">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20260729153134926_xbrl_20230728052426602_Fact_140"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_169"
      unitRef="usd">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_170"
      unitRef="usd">230000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_173"
      unitRef="usd">-59266000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_174"
      unitRef="usd">-2269000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_175"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_176"
      unitRef="usd">8870000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_179"
      unitRef="usd">147000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_180"
      unitRef="usd">35000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_181"
      unitRef="usd">147000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_182"
      unitRef="usd">8905000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240731010623321_xbrl_20240301111408147"
      unitRef="usd">749000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240731010623321_xbrl_20240301111411299"
      unitRef="usd">166000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20220719232250681"
      unitRef="usd">-80317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728053102843"
      unitRef="usd">-11762000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_185"
      unitRef="usd">90597000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="FFact_186"
      unitRef="usd">18229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_187"
      unitRef="usd">10280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20250630"
      decimals="-3"
      id="FFact_188"
      unitRef="usd">6467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728044639062"
      unitRef="usd">-110000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728044646863"
      unitRef="usd">8000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230728052431875_Fact_139"
      unitRef="usd">115000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20230728052431875_Fact_140"
      unitRef="usd">64000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729162756611">
    &lt;div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&lt;span id="a_STATEMENTS"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;NOTE 1&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;:- GENERAL&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;C&lt;/span&gt;&lt;/span&gt;ompugen Ltd. (the &#x201c;Company&#x201d;) is a clinical-stage therapeutic discovery and development company utilizing Unigen&#x2122;, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. The Company&#x2019;s innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, the Company&#x2019;s anti-TIGIT antibody, is being developed by AstraZeneca plc (&#x201c;AstraZeneca&#x201d;) pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), the Company&#x2019;s potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, the Company has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity.&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is headquartered in Holon, Israel. Its clinical development activities operate from the Company&#x2019;s headquarters in Israel and from its United States subsidiary, Compugen USA, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred losses in the amount of $14,675 during the six months ended June 30, 2026, has an accumulated deficit of $468,090 as of June 30, 2026, and has an accumulated negative cash flow from operating activities in the amount of $21,947 for the six months ended June 30, 2026. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the date of issuance of these interim consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif"&gt;&#160;&lt;/p&gt;
      &lt;div style="margin-top:0px;margin-bottom:0px"&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the said exclusive license agreement with AstraZeneca (such agreement, as amended from time to time, the &#x201c;AstraZeneca License Agreement&#x201d;), Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development and commercial activities under the agreement. In connection with the AstraZeneca License Agreement, AstraZeneca developed rilvegostomig, a novel PD-1/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902. Rilvegostomig entered the clinic in September 2021, the first patient dosing in the first indication of its Phase 3 study took place in December 2023, and first patient dosing in the second indication Phase 3 study took place in May 2024. From the initial date of the AstraZeneca License Agreement until the recent amendment thereto dated December 16, 2025, Compugen had received a $10,000 upfront payment and $30,500 milestone payments out of up to $200,000 that the Company is eligible to receive in development, regulatory and commercial milestones for the first commercialized product. Compugen is also eligible to receive&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 16, 2025, the parties to the AstraZeneca License Agreement entered into an amendment thereto whereby the Company sold to AstraZeneca a portion of the existing royalty interest in rilvegostomig for a $65,000 upfront payment which was paid in 2025 and for an addition of $25,000 pertaining to the next potential milestone payment to be paid to the Company, which is the first acceptance of the Biologics License Application (&#x201c;BLA&#x201d;). Following the amendment, the Company remains eligible for tiered royalties of up to mid-single digit on future sales under the AstraZeneca License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 84.3pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 18, 2023, the Company entered into an exclusive license agreement (the &#x201c;License Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) pursuant to which the Company granted Gilead an exclusive license under the Company&#x2019;s then pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#x2019;s COM503 product candidate, now named GS-0321, and additional products that may be so developed by Gilead (together with GS-0321, the &#x201c;Licensed Products&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $60,000 in January 2024. The Company has continued to develop GS-0321 during the initial development term, which included conducting activities defined within the agreement to advance GS-0321 through the clearance of an investigational new drug application (&#x201c;IND&#x201d;) and further. Gilead paid to the Company $30,000 in the form of a milestone payment upon clearance of the IND for GS-0321. The Company is also eligible to receive up to approximately $758,000 in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive a single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.5pt;text-align:justify;text-indent:-1.2pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is responsible for conducting a Phase 1 clinical trial for GS-0321, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the GS-0321 drug supply), with Gilead providing at no cost its &lt;span&gt;zimberelimab&lt;/span&gt; antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Upon completion of the Phase 1 clinical trial for GS-0321, the Company will initiate the transfer of development activities related to GS-0321 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.&lt;br/&gt;&#160;&lt;br/&gt;In addition, under certain circumstances, the Company is obligated to cause the manufacture and supply of agreed quantities of GS-0321 to Gilead, if and when requested by Gilead, and in consideration therefor the Company is entitled to consideration equal to its costs plus a 10% markup. The Company has identified this supply as a separate performance obligation and recognizes the associated revenue at the point in time when control of each batch transfers to Gilead&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.5pt;text-align:justify;text-indent:-31.5pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.&lt;br/&gt;&#160;&lt;br/&gt;Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gilead withheld at source 15% from the upfront payment and IND clearance milestone amounts paid to the Company in January 2024 and in September 2024, respectively, and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect to change of control and others.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230802202124242"
      unitRef="usd">-14675000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20230802202128417"
      unitRef="usd">-468090000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20230802202134755"
      unitRef="usd">-21947000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="Fxbrl_20230802201751108"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="Fxbrl_20230802201758034"
      unitRef="usd">30500000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20180330"
      decimals="-3"
      id="Fxbrl_20230802201804474"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:NonRefundableUpfrontPayment
      contextRef="C_20251201to20251216"
      decimals="-6"
      id="Fxbrl_20260729163055500"
      unitRef="usd">65000000000</cgen:NonRefundableUpfrontPayment>
    <cgen:MilestonePaymentReceivable
      contextRef="C_20251201to20251216"
      decimals="-6"
      id="Fxbrl_20260729163137427"
      unitRef="usd">25000000000</cgen:MilestonePaymentReceivable>
    <cgen:NonRefundableUpfrontPayment
      contextRef="C_20240101to20240131"
      decimals="-6"
      id="Fxbrl_20240730185336641"
      unitRef="usd">60000000000</cgen:NonRefundableUpfrontPayment>
    <cgen:MilestonePaymentReceivable
      contextRef="C_20240101to20240131"
      decimals="-6"
      id="Fxbrl_20240730185916012"
      unitRef="usd">30000000000</cgen:MilestonePaymentReceivable>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram
      contextRef="C_20240131"
      decimals="-6"
      id="Fxbrl_20240730190011813"
      unitRef="usd">758000000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram>
    <cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid
      contextRef="C_20240101to20240131"
      decimals="2"
      id="Fxbrl_20240730190156394"
      unitRef="Pure">0.15</cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250731230210971">
    &lt;div&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2025. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2025, are applied consistently in these interim consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 76.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Recently issued accounting pronouncements &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 76.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure (Subtopic 220-40), Disaggregation of Income Statement Expenses, which requires disclosure of disaggregated information about certain expense captions presented in the Consolidated Statements of Operations as well as disclosure about selling expense. The guidance will be effective for the Company for annual periods beginning January 1, 2027, and interim periods beginning January 1, 2028, with early adoption permitted. It could be applied either prospectively or retrospectively. The Company is currently evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 76.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which establish guidance on the recognition, measurement and presentation of a government grant received by a business entity. The guidance will be effective for the Company for annual periods beginning after December 15, 2028, and interim periods beginning January 1, 2029, with early adoption permitted. The Company is currently evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 76.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which establish final guidance clarifying the current interim disclosure requirements. The guidance creates a comprehensive list of interim disclosures required under US GAAP and incorporates a disclosure principle that requires disclosures at interim periods when an event or change that has a material effect on an entity has occurred since the previous year end. The guidance will be effective for the Company for interim reporting periods within annual periods beginning after December 15, 2027. The Company is currently evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <cgen:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250801113200561">
        &lt;div&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Recently issued accounting pronouncements &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 76.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure (Subtopic 220-40), Disaggregation of Income Statement Expenses, which requires disclosure of disaggregated information about certain expense captions presented in the Consolidated Statements of Operations as well as disclosure about selling expense. The guidance will be effective for the Company for annual periods beginning January 1, 2027, and interim periods beginning January 1, 2028, with early adoption permitted. It could be applied either prospectively or retrospectively. The Company is currently evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 76.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which establish guidance on the recognition, measurement and presentation of a government grant received by a business entity. The guidance will be effective for the Company for annual periods beginning after December 15, 2028, and interim periods beginning January 1, 2029, with early adoption permitted. The Company is currently evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 76.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which establish final guidance clarifying the current interim disclosure requirements. The guidance creates a comprehensive list of interim disclosures required under US GAAP and incorporates a disclosure principle that requires disclosures at interim periods when an event or change that has a material effect on an entity has occurred since the previous year end. The guidance will be effective for the Company for interim reporting periods within annual periods beginning after December 15, 2027. The Company is currently evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
      </cgen:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20240730190633689">
    &lt;div&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3:- UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating results for the six-month period ended June&#160;30, 2026, are not necessarily indicative of the results that may be expected for the year ended December 31, 2026.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250731231030230">
    &lt;div&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;NOTE 4:- MARKETABLE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following is a summary of available-for-sale marketable securities as of June 30, 2026 and December 31, 2025:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized gains&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of June 30, 2026:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:52%;text-align:left;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;39,713&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;39,682&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2025:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,276&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,284&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 58.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of June 30, 2026, the Company had no significant unrealized losses related to marketable securities (which were accumulated in a period of less than 12 months) and determined the unrealized losses are not due to credit related losses, therefore, the Company did not record an allowance for credit losses for its available-for-sale marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 58.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of June 30, 2026, all of the Company&#x2019;s available-for-sale marketable securities were due within one year.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 58.3pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company had no sales of marketable securities during the six-month periods ended June 30, 2026 and 2025, and accordingly no realized gains or losses were recorded. Proceeds from maturities of available-for-sale marketable securities during the six month periods ended June 30, 2026, and 2025 were $&lt;span&gt;8,970&lt;/span&gt;&#160;and $21,643, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250731231234081">
        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized gains&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of June 30, 2026:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:52%;text-align:left;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;39,713&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;39,682&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2025:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,276&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,284&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101843888"
      unitRef="usd">39713000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101901825"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101905592"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101909777"
      unitRef="usd">39682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_xbrl_20230728101843888"
      unitRef="usd">9276000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_xbrl_20230728101901825"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_xbrl_20230728101905592"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_xbrl_20230728101909777"
      unitRef="usd">9284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20250731232522472"
      unitRef="usd">8970000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20250731232532543"
      unitRef="usd">21643000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729145554421">
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 5:- FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&#160;&lt;/p&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="font-weight:bold;text-align:justify"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:justify"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair value measurements&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;as of&lt;/strong&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center;border-bottom:1pt solid black;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;December&#160;31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                    &lt;td style="font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-decoration:underline;text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                    &lt;td style="width:64%;text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Money market funds&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,124&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,043&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                    &lt;td style="text-decoration:underline;text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;39,682&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,284&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729145602903">
          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="font-weight:bold;text-align:justify"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:justify"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair value measurements&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;as of&lt;/strong&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center;border-bottom:1pt solid black;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;December&#160;31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                    &lt;td style="font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-decoration:underline;text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                    &lt;td style="width:64%;text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Money market funds&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,124&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,043&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                    &lt;td style="text-decoration:underline;text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="vertical-align:bottom"&gt;
                    &lt;td style="text-align:justify;padding-bottom:1pt;padding-left:4.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S. Treasury&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;39,682&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,284&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_20260630_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20250731233130974"
      unitRef="usd">4124000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_20251231_usgaapFairValueByAssetClassAxis_usgaapMoneyMarketFundsMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20250731233145577"
      unitRef="usd">4043000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20250731233202783"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20250731233221070"
      unitRef="usd">35290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20260729145326918_xbrl_20250731233202783"
      unitRef="usd">39682000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapUSTreasurySecuritiesMember"
      decimals="-3"
      id="Fxbrl_20260729145326918_xbrl_20250731233221070"
      unitRef="usd">9284000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729151433053">
    &lt;div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify;text-indent:0in"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;NOTE 6:- COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company provided bank guarantees in the amount of $436 in favor of its offices and car leases in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (&#x201c;IIA&#x201d;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the six-month periods ended June 30, 2026 and 2025, the Company did not record any royalties to the IIA as cost of revenue in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.05pt;text-align:justify;text-indent:-28.35pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 10pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued and net of outstanding credit balance, totaled $8,433.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#x201c;Contingent Fees&#x201d;). For the six-month periods ended June 30, 2026 and 2025, the Company did not incur Contingent Fees.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#x201c;CLA&#x201d;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2026 and 2025, the Company did not incur milestone payments.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement, the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2026 and 2025 the Company did not incur in the research and development any expenses of a milestone payment.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20230802221055283"
      unitRef="usd">436000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20260101to20260630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062450451"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20260101to20260630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062556413"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="C_20260101to20260630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062648820"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <cgen:MaximumAmountToBeRepaidAsPercentage
      contextRef="C_20260101to20260630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20260729151447446"
      unitRef="Pure">1</cgen:MaximumAmountToBeRepaidAsPercentage>
    <cgen:RoyaltyContingentObligations
      contextRef="C_20260630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="-3"
      id="Fxbrl_20220720062746091"
      unitRef="usd">8433000</cgen:RoyaltyContingentObligations>
    <cgen:PercentageOfRoyaltiesOnNetSales
      contextRef="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember"
      decimals="2"
      id="Fxbrl_20240805154741994"
      unitRef="Pure">0.01</cgen:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250801012531376">
    &lt;div&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 7:- SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:-56.7pt"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuance of Shares:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#x201c;Leerink Partners&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#x201c;at the market offering&#x201d; (ATM). The offer and sale of our ordinary shares, if any, are and have been made pursuant to the base prospectus included in the Company&#x2019;s shelf registration statements on Form F-3 (as declared effective on June 27, 2023 and June 8, 2026), as supplemented by the applicable prospectus supplement pertaining to the ATM. As of June 30, 2026, 7,767,626 shares were issued and sold through the ATM, with proceeds to the Company of approximately $14,152 (net of $943 issuance expenses). Pursuant to the existing prospectus supplement, the Company may offer and sell up to an additional $100,000 of its ordinary shares.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share option plan:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Transactions related to the grant of options to employees, directors and non-employees under the Company&#x2019;s 2010 Share Option Plan, as amended, during the six-month period ended June 30, 2026, were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.05pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise&lt;br/&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Aggregate intrinsic &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:52%;text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at the beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,628,743&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,600&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(142,435&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(105,369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(722,330&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding as of June 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,682,209&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,324&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable as of June 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,882,971&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.05pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six-month period ended June 30, 2026, the Company&#x2019;s Board of Directors granted 23,600 options to purchase ordinary shares of the Company to employees. The exercise prices for such options range from $1.76 to $2.90 per share, with vesting to occur within  four years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.05pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.05pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div&gt;
        &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&#160;&lt;/p&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                  &lt;td style="text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87.1%-91.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90.6%-91.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:White"&gt;
                  &lt;td style="text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.76%-4.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.07%-4.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                  &lt;td style="width:76%;text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:White"&gt;
                  &lt;td style="text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.13-5.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

      &lt;/div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average fair value of options granted during the six-month periods ended June 30, 2026 and 2025 were $1.33 and $1.20, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"&gt;

          &lt;tr style="vertical-align:top"&gt;
            &lt;td style="width:46.5pt"&gt;&lt;/td&gt;
            &lt;td style="width:28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A summary of RSUs activity during the six-month period ended June 30, 2026 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 84.45pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of RSUs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average grant date per value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:76%;text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs outstanding at the beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;567,400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;19,200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(29,645&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(28,442&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.61&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs net settled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(388&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.69&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unvested RSUs outstanding as of June 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;528,125&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.05pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, the total unrecognized estimated compensation cost related to non-vested share options and RSUs granted prior to that date was $2,203 which is expected to be recognized over a weighted average period of approximately 2.63 years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 85.05pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The stock-based compensation expenses related to share options and RSU's are included as follows in the expense categories:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.85pt;text-align:justify"&gt;&#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="border-bottom:1pt solid black;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:Black 1pt solid;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="border-bottom:Black 1pt solid;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unaudited&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;210&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;331&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;570&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20260101to20260630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="INF"
      id="Fxbrl_20260731165923434"
      unitRef="Shares">7767626</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20260101to20260630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20260731165958193"
      unitRef="usd">14152000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20260101to20260630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20260731170009300"
      unitRef="usd">943000</us-gaap:PaymentsOfStockIssuanceCosts>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20260731165942995"
      unitRef="usd">100000000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250801015946074">
        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise&lt;br/&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Aggregate intrinsic &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:52%;text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at the beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,628,743&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,600&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(142,435&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(105,369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(722,330&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding as of June 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,682,209&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,324&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable as of June 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,882,971&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20251231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214617051"
      unitRef="Shares">8628743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20251231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="2"
      id="Fxbrl_20240730214440322_Fact_0000000000541"
      unitRef="USD_per_share">4.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="Fxbrl_20240731023155518">P5Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20251231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20240731020116330"
      unitRef="usd">796000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440323_Fact_0000000000545"
      unitRef="Shares">23600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440323_Fact_0000000000546"
      unitRef="USD_per_share">1.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214715608_xbrl_20240730214440324_Fact_0000000000549"
      unitRef="Shares">142435</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214715608_xbrl_20240730214440324_Fact_0000000000550"
      unitRef="USD_per_share">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20250801015714139"
      unitRef="usd">202000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000549"
      unitRef="Shares">105369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000550"
      unitRef="USD_per_share">1.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000551"
      unitRef="Shares">722330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000552"
      unitRef="USD_per_share">4.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000553"
      unitRef="Shares">7682209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000554"
      unitRef="USD_per_share">4.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="Fxbrl_20240730214440324_Fact_0000000000555">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20240730214440324_Fact_0000000000556"
      unitRef="usd">2324000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440325_Fact_0000000000557"
      unitRef="Shares">5882971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440325_Fact_0000000000558"
      unitRef="USD_per_share">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="Fxbrl_20240730214440325_Fact_0000000000559">P4Y2M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20240730214440325_Fact_0000000000560"
      unitRef="usd">1190000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="Fxbrl_20220720040533152"
      unitRef="Shares">23600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="Fxbrl_20220720040558485"
      unitRef="USD_per_share">1.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="FFact_251"
      unitRef="USD_per_share">2.9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="C_20260101to20260630" id="FFact_252">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260730180736022">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom"&gt;
                  &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                  &lt;td style="text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87.1%-91.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90.6%-91.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:White"&gt;
                  &lt;td style="text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.76%-4.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.07%-4.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                  &lt;td style="width:76%;text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="vertical-align:bottom;background-color:White"&gt;
                  &lt;td style="text-align:justify;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.13-5.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20260101to20260630_srtRangeAxis_srtMinimumMember"
      decimals="3"
      id="Fxbrl_20260730180759995"
      unitRef="Pure">0.871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20260101to20260630_srtRangeAxis_srtMaximumMember"
      decimals="3"
      id="Fxbrl_20260730180806171"
      unitRef="Pure">0.914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20250101to20250630_srtRangeAxis_srtMinimumMember"
      decimals="3"
      id="Fxbrl_20260730180811818"
      unitRef="Pure">0.906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20250101to20250630_srtRangeAxis_srtMaximumMember"
      decimals="3"
      id="Fxbrl_20260730180817452"
      unitRef="Pure">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20260101to20260630_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="Fxbrl_20260730180824035"
      unitRef="Pure">0.0376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20260101to20260630_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="Fxbrl_20260730180832131"
      unitRef="Pure">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20250101to20250630_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="Fxbrl_20260730180838681"
      unitRef="Pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20250101to20250630_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="Fxbrl_20260730180845797"
      unitRef="Pure">0.0437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20260730180859610"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20250101to20250630"
      decimals="2"
      id="Fxbrl_20260730180853434"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20260101to20260630_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20260730180906205">P4Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20260101to20260630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20260730180913297">P5Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20250101to20250630"
      id="Fxbrl_20260730180919996">P4Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="FFact_267"
      unitRef="USD_per_share">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="FFact_268"
      unitRef="USD_per_share">1.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250801021515794">
        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of RSUs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average grant date per value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:76%;text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs outstanding at the beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;567,400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:9%;font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;19,200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(29,645&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(28,442&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.61&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;RSUs net settled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(388&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="font-weight:normal;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.69&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-5.65pt;padding-left:8.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-5.65pt;padding-left:8.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unvested RSUs outstanding as of June 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;528,125&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:normal;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;font-weight:normal;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;font-weight:normal;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20251231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250801021804324"
      unitRef="Shares">567400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20251231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20250801021903116"
      unitRef="USD_per_share">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250801022115264"
      unitRef="Shares">19200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20250801022226050"
      unitRef="USD_per_share">1.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20260729165514440_xbrl_20250801022326211"
      unitRef="Shares">29645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20260729165514440_xbrl_20250801022419527"
      unitRef="USD_per_share">1.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250801022326211"
      unitRef="Shares">28442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20250801022419527"
      unitRef="USD_per_share">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNetSettledInPeriod
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20260729165517634_xbrl_20250801022326211"
      unitRef="Shares">388</cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNetSettledInPeriod>
    <cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNetSettledInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20260729165517634_xbrl_20250801022419527"
      unitRef="USD_per_share">1.69</cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNetSettledInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250801022503472"
      unitRef="Shares">528125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20260630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20250801022715518"
      unitRef="USD_per_share">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_271"
      unitRef="usd">2203000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20260101to20260630" id="FFact_272">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729164458920">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:74.85pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="border-bottom:1pt solid black;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:Black 1pt solid;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="border-bottom:Black 1pt solid;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unaudited&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;210&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;331&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;570&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20260101to20260630_cgenStatementOfLocationIncomeBalanceAxis_cgenResearchAndDevelopmentExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455558_Fact_0000000000578"
      unitRef="usd">210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20250101to20250630_cgenStatementOfLocationIncomeBalanceAxis_cgenResearchAndDevelopmentExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455558_Fact_0000000000579"
      unitRef="usd">454000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20260101to20260630_cgenStatementOfLocationIncomeBalanceAxis_cgenSellingAndMarketingExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455562_Fact_0000000000581"
      unitRef="usd">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20250101to20250630_cgenStatementOfLocationIncomeBalanceAxis_cgenSellingAndMarketingExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455562_Fact_0000000000582"
      unitRef="usd">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20260101to20260630_cgenStatementOfLocationIncomeBalanceAxis_cgenGeneralAndAdministrativeExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455565_Fact_0000000000584"
      unitRef="usd">331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20250101to20250630_cgenStatementOfLocationIncomeBalanceAxis_cgenGeneralAndAdministrativeExpensesMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455565_Fact_0000000000585"
      unitRef="usd">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214502424_Fact_0000000000587"
      unitRef="usd">570000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20250101to20250630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214502424_Fact_0000000000588"
      unitRef="usd">987000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250801002931989">
    &lt;div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;NOTE 8:- FINANCIAL AND OTHER INCOME, NET&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&#160;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:76%;text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,517&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,048&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;310&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,191&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
  </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250801002942364">
        &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="width:76%;text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,517&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,048&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;310&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:1pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom"&gt;
              &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
              &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,191&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_290"
      unitRef="usd">2517000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_291"
      unitRef="usd">2048000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20240730200046696_Fact_290"
      unitRef="usd">148000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20240730200046696_Fact_291"
      unitRef="usd">310000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20220720002002984"
      unitRef="usd">526000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_293"
      unitRef="usd">-43000</us-gaap:OtherNonoperatingIncomeExpense>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20260729153412647"
      unitRef="usd">3191000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_295"
      unitRef="usd">2315000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729154356764">
    &lt;div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;NOTE 9:- SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table presents selected financial information with respect to the Company&#x2019;s single operating segment and includes information about segment revenues and significant segment expenses, for the six months ended June 30, 2026 and 2025:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:1pt solid black"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:1pt solid black"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total Revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,541&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preclinical&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,858&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,659&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clinical&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,824&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,982&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SG&amp;amp;A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,438&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,851&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,189&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,314&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes on income&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify;padding-bottom:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other segment expenses*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;510&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,872&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,523&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*Other segment expense during the six months ended June 30, 2026 and 2025 includes share-based compensation and other adjustments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;

      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 10pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operations in Israel include research and development, clinical operations, general and administrative, marketing and business development, and operations in the United States include clinical operations. Total revenues are attributed to geographic areas based on the location of the end customer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;The following represents the total revenue for the six-month periods ended June 30, 2026 and 2025 by region based on the invoicing address of customers&lt;/span&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,541&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,541&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 28.1pt;text-align:left;text-indent:28.1pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Contract Balances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 28.1pt;text-align:left;text-indent:28.1pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Of the $35,913 and $43,677 of the deferred revenue recorded as of December 31, 2025 and 2024, respectively, the Company recognized $4,778 and $3,541 as revenue during the six months periods ended June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.2pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.2pt;text-align:left"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s remaining performance obligations are comprised of revenue not yet recognized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.2pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The remaining performance obligations are attributable to Phase 1 research and development activities and to the drug supply of GS-0321 to Gilead performed by the Company. As of June 30, 2026, the aggregate amount of the transaction price allocated to remaining performance obligations was $31,136 attributable to Phase 1 research and development activities and $680 attributable to the drug supply of GS-0321 to Gilead that the Company expects to recognize as revenue. As of June 30, 2026, the Company expects to recognize 35% of the remaining performance obligation attributable to Phase 1 research and development activities over the next 12 months and the remainder through 2029. The Company expects to recognize 100% of the remaining performance obligation attributable to the drug supply of GS-0321 to Gilead as revenue over the next 12 months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729154403710">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:1pt solid black"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:1pt solid black"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total Revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,541&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preclinical&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,858&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,659&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clinical&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,824&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,982&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SG&amp;amp;A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,438&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,851&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,189&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,314&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes on income&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify;padding-bottom:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other segment expenses*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;510&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,872&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:justify;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(14,523&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*Other segment expense during the six months ended June 30, 2026 and 2025 includes share-based compensation and other adjustments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033201488"
      unitRef="usd">4778000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033208072"
      unitRef="usd">3541000</us-gaap:Revenues>
    <cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_83"
      unitRef="usd">7858000</cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_87"
      unitRef="usd">6659000</cgen:PreclinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:ClinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_93"
      unitRef="usd">8824000</cgen:ClinicalAmountOfExpenseForResearchAndDevelopment>
    <cgen:ClinicalAmountOfExpenseForResearchAndDevelopment
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_97"
      unitRef="usd">6982000</cgen:ClinicalAmountOfExpenseForResearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_103"
      unitRef="usd">5438000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_107"
      unitRef="usd">4851000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_113"
      unitRef="usd">3189000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_117"
      unitRef="usd">2314000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_123"
      unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_127"
      unitRef="usd">14000</us-gaap:IncomeTaxExpenseBenefit>
    <cgen:OtherSegmentExpenses
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_133"
      unitRef="usd">510000</cgen:OtherSegmentExpenses>
    <cgen:OtherSegmentExpenses
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_137"
      unitRef="usd">1872000</cgen:OtherSegmentExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_153"
      unitRef="usd">-14675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630_usgaapStatementBusinessSegmentsAxis_cgenSingleOperatingSegmentMember"
      decimals="-3"
      id="Fxbrl_20250801033336772_157"
      unitRef="usd">-14523000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729154410206">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,541&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,541&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20260101to20260630_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20250801034136570_53"
      unitRef="usd">4778000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20250101to20250630_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20250801034136570_57"
      unitRef="usd">3541000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20260101to20260630_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="Fxbrl_20250801034136570_63"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20250101to20250630_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="Fxbrl_20250801034136570_67"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20250801034136570_83"
      unitRef="usd">4778000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20250801034136570_87"
      unitRef="usd">3541000</us-gaap:Revenues>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250801032819121"
      unitRef="usd">35913000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250801032830284"
      unitRef="usd">43677000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="Fxbrl_20250801032851850"
      unitRef="usd">4778000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="Fxbrl_20250801032910150"
      unitRef="usd">3541000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <cgen:ResearchAndDevelopmentActivitiesRemainingPerformanceObligationAmount
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20250801032958600"
      unitRef="usd">31136000</cgen:ResearchAndDevelopmentActivitiesRemainingPerformanceObligationAmount>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_20260630"
      decimals="-3"
      id="Fxbrl_20260729154540795"
      unitRef="usd">680000</us-gaap:RevenueRemainingPerformanceObligation>
    <cgen:ResearchAndDevelopmentActivitiesRemainingPerformanceObligationPercentage
      contextRef="C_20260630"
      decimals="2"
      id="Fxbrl_20250801032946688"
      unitRef="Pure">0.35</cgen:ResearchAndDevelopmentActivitiesRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="C_20260630"
      decimals="2"
      id="Fxbrl_20260729154554228"
      unitRef="Pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729153858172">
    &lt;div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;NOTE 10:- RELATED PARTY BALANCES AND TRANSACTIONS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;Balances with related parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                  &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;December&#160;31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="width:76%;text-align:left;padding-left:2.85pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unaudited&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;Related parties' expenses:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six months ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;padding-left:2.85pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;padding-left:2.85pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six months ended June 30, 2026, and 2025, the Company received research and development services related to cancer studies in animal models, and breeding and maintenance of animals (mice) from &#x201c;Ramot at Tel- Aviv University Ltd.&#x201d; (&#x201c;Ramot&#x201d;). Ramot is considered a related party of the Company due to the fact that a member of the Company&#x2019;s Board of Directors is serving as a director of Ramot. The transaction was at arm&#x2019;s length.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729153912319">
        &lt;div&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;Balances with related parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                  &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;December&#160;31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="width:76%;text-align:left;padding-left:2.85pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unaudited&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;font-weight:bold;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;Related parties' expenses:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0in"&gt;&#160;&lt;/p&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid"&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six months ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 2.85pt;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;padding-left:2.85pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:9%;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;padding-left:2.85pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cgen:TradeAndOtherPayablesRelatedParties
      contextRef="C_20260630"
      decimals="-3"
      id="FFact_298"
      unitRef="usd">45000</cgen:TradeAndOtherPayablesRelatedParties>
    <cgen:TradeAndOtherPayablesRelatedParties
      contextRef="C_20251231"
      decimals="-3"
      id="FFact_299"
      unitRef="usd">32000</cgen:TradeAndOtherPayablesRelatedParties>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="FFact_300"
      unitRef="usd">53000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="FFact_301"
      unitRef="usd">60000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260729153717518">
    &lt;div&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;NOTE 11:- LOSSES PER SHARE&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;For the six months ended June 30, 2026 and 2025, the total weighted average number of shares related to outstanding options and RSUs excluded from the calculations of diluted net loss per share were 8,424,235 and 8,797,858, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 46.5pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:normal"&gt;The following table sets forth the computation of basic and diluted losses per share for the six-month periods ended June 30, 2026 and 2025:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt;text-align:justify;text-indent:0pt"&gt;&#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,523&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;94,598,696&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92,917,554&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250801030115644"
      unitRef="Shares">8424235</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20250801030122481"
      unitRef="Shares">8797858</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250801005749356">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif;margin-left:46.5pt"&gt;

              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="font-weight:bold;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td style="font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="width:76%;text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:1%;border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:9%;border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,523&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:1%;padding-bottom:2.5pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;94,598,696&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92,917,554&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom"&gt;
                &lt;td style="text-align:left;text-indent:-8.5pt;padding-left:11.35pt"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255)"&gt;
                &lt;td style="text-align:left;padding-bottom:2.5pt;text-indent:-8.5pt;padding-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:2.5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="border-bottom:Black 2.5pt double;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="padding-bottom:1.2pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="-3"
      id="F20240730141359513_1"
      unitRef="usd">-14675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="-3"
      id="F20240730141359513_2"
      unitRef="usd">-14523000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="Fxbrl_20240730195604484"
      unitRef="Shares">94598696</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="F20240730141359513_3"
      unitRef="Shares">94598696</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="Fxbrl_20240730195622412"
      unitRef="Shares">92917554</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="F20240730141359513_4"
      unitRef="Shares">92917554</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="F20240730141359514_12"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20260101to20260630"
      decimals="INF"
      id="F20240730141359514_7"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="F20240730141359514_13"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20250101to20250630"
      decimals="INF"
      id="F20240730141359514_8"
      unitRef="USD_per_share">-0.16</us-gaap:EarningsPerShareBasic>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20220727223630806"
          xlink:label="Fxbrl_20220727223630806"
          xlink:type="locator"/>
        <link:footnote id="FN20250801113847360" xlink:label="FN20250801113847360" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount lower than $1</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220727223630806"
          xlink:to="FN20250801113847360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250731221914224_xbrl_20220727223630806"
          xlink:label="Fxbrl_20250731221914224_xbrl_20220727223630806"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250731221914224_xbrl_20220727223630806"
          xlink:to="FN20250801113847360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20260729145918756_xbrl_20220727223630806"
          xlink:label="Fxbrl_20260729145918756_xbrl_20220727223630806"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20260729145918756_xbrl_20220727223630806"
          xlink:to="FN20250801113847360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
          xlink:label="Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20260729225131885_xbrl_20260729144653897_xbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
          xlink:to="FN20250801113847360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250801033336772_133"
          xlink:label="Fxbrl_20250801033336772_133"
          xlink:type="locator"/>
        <link:footnote id="FN20250801140949948" xlink:label="FN20250801140949948" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other segment expense (income) during the six months ended June 30, 2025 and 2024 includes property and equipment depreciation, GS-0321 asset of set-up activities, share-based compensation and other adjustments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250801033336772_133"
          xlink:to="FN20250801140949948"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250801033336772_137"
          xlink:label="Fxbrl_20250801033336772_137"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250801033336772_137"
          xlink:to="FN20250801140949948"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
